ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 Drug Profile

Summary for Tradename: ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5

Ingredient-type	Serum Albumin
Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Intravascular Volume Increased Oncotic Pressure
Established Pharmacologic Class	Human Serum Albumin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138		2031-10-11	Patent claims search
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138		2033-03-11	Patent claims search
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138		2034-10-03	Patent claims search
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138		2032-03-02	Patent claims search

ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 Market Analysis and Financial Projection Experimental

Albumin Market Dynamics and Financial Trajectory: A Comprehensive Overview

Introduction to Albumin

Albumin, a major protein found in blood plasma, plays a crucial role in various medical and pharmaceutical applications. Products like ALBUKED, PLASBUMIN-20, PLASBUMIN-25, and PLASBUMIN-5 are integral to the albumin market, which is experiencing significant growth driven by several key factors.

Market Size and Growth Projections

The global albumin market has been valued at approximately USD 5.6 billion in 2023 and is projected to grow at a Compound Annual Growth Rate (CAGR) of over 6.5% from 2024 to 2032, reaching a forecasted value of USD 10.1 billion by 2032[5].

Type Analysis: Human Serum Albumin Dominance

Human serum albumin (HSA) dominates the market, accounting for the largest share in terms of revenue. This dominance is attributed to the increasing demand for HSA in drug development, pharmaceutical R&D activities, and therapeutic applications. The HSA segment is expected to continue its growth trajectory during the forecast period[2][4].

Application Analysis: Therapeutics Sector Leads

The therapeutics sector is anticipated to lead the market during the forecast period. This is due to the growing demand for albumin in drug discovery, the increasing prevalence of cardiac disorders, trauma, burns, and cancer cases. Albumin products like PLASBUMIN-20, PLASBUMIN-25, and PLASBUMIN-5 are crucial in treating hypovolemic shock, burn therapy, and hypoproteinemia[1][2][4].

End-User Analysis: Hospitals & Clinics and Pharmaceutical Industries

Hospitals and clinics are the major end-users of albumin products, driven by the increased prescription of drugs for therapeutic treatments. This segment is expected to record a considerable CAGR during the forecast period. The pharmaceutical and biotechnology industry segment is also growing rapidly due to the increasing use of albumin in developing new therapeutic solutions and conducting clinical trials[1][2][5].

Clinical Applications of Albumin Products

Albumin products such as PLASBUMIN are used for emergency treatment of hypovolemic shock, burn therapy, and hypoproteinemia. For instance, PLASBUMIN-25 acts as a plasma volume expander, drawing fluid from extravascular tissues into the circulation, thereby increasing total blood volume and reducing hemoconcentration and whole blood viscosity[3].

Market Drivers

Several factors are driving the growth of the albumin market:

• Increasing Prevalence of Diseases: Conditions such as hypoalbuminemia, burns, trauma, liver cirrhosis, and cardiac surgeries significantly propel the market growth[4].
• Growing Demand in R&D: The surge in research and development activities in the pharmaceutical and biotechnology sectors increases the demand for albumin[1][2][5].
• Technological Advancements: Advances in biotechnology and the increasing use of albumin in drug formulation and delivery systems contribute to market expansion[5].
• Awareness and Blood Donation: Initiatives aimed at raising awareness about blood donation positively impact the supply of human plasma, a key source of albumin[4].

Regional Market Dynamics

North America generated the largest revenue in 2022, but the Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. This regional growth is driven by increasing healthcare awareness and the rising incidence of chronic diseases[4][5].

Key Players and Competitive Landscape

The albumin market is characterized by several key players, including global pharmaceutical companies, biotechnology firms, and specialized manufacturers. Companies like CSL Behring, Grifols, Baxter International Inc., Octapharma, and China Biologic Products Holdings, Inc. are significant contributors to the albumin business. These companies compete based on factors such as product quality, innovation, pricing, distribution networks, and regulatory compliance[5].

Financial Trajectory

The financial trajectory of the albumin market is robust, with a projected CAGR of 6.2% to 6.5% from 2023 to 2032. Here are some key financial projections:

• 2022 Market Size: USD 5.4 billion[4].
• 2023 Market Size: USD 5.6 billion[5].
• 2032 Forecasted Value: USD 9.9 billion to USD 10.1 billion[4][5].

Challenges and Opportunities

While the market is growing, there are challenges such as the high cost of albumin products and the need for stringent regulatory compliance. However, opportunities abound in the form of increasing non-therapeutic applications of albumin, advancements in biotechnology, and growing demand for albumin in emerging markets[5].

Key Takeaways

• The albumin market is driven by the increasing prevalence of diseases, growing demand in R&D, and technological advancements.
• Human serum albumin dominates the market, with the therapeutics sector leading in terms of application.
• Hospitals and clinics, along with the pharmaceutical and biotechnology industries, are major end-users.
• The market is expected to grow at a CAGR of 6.2% to 6.5% from 2023 to 2032.
• Key players are focusing on product quality, innovation, and regulatory compliance to maintain market share.

FAQs

Q: What is the primary use of albumin products like PLASBUMIN-25? A: Albumin products like PLASBUMIN-25 are primarily used for emergency treatment of hypovolemic shock, burn therapy, and hypoproteinemia, acting as plasma volume expanders[3].

Q: Which segment dominates the albumin market in terms of revenue? A: The human serum albumin segment dominates the market in terms of revenue, driven by its increasing demand in drug development and therapeutic applications[2][4].

Q: What are the key drivers of the albumin market growth? A: The key drivers include the increasing prevalence of diseases, growing demand in R&D, technological advancements, and initiatives aimed at raising awareness about blood donation[1][4][5].

Q: Which region is expected to grow at the highest CAGR during the forecast period? A: The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period, driven by increasing healthcare awareness and the rising incidence of chronic diseases[4][5].

Q: Who are the major players in the albumin market? A: Major players include CSL Behring, Grifols, Baxter International Inc., Octapharma, and China Biologic Products Holdings, Inc.[5].

Cited Sources

1. Fortune Business Insights: Albumin Market | Key products, Applications, End-users [2032]
2. Market.us: Albumin Market | Report, Size, share Analysis | CAGR of 6.4%
3. RxList: Plasbumin (Albumin - Human Solution for Injection ) - RxList
4. Allied Market Research: Albumin Market Size, Share | Growth Drivers | Forecast- 2032
5. GMI Insights: Albumin Market Size & Share, Analysis Report 2024-2032